Human Papillomavirus-Related Malignant Neoplasm Clinical Trial
Official title:
Safety Study of Transcription Activator-like Effector Nucleases T512 in HPV16-infected Subjects
This is an single arm clinical study of the safety and efficacy of T512 to possibly treat cervical intraepithelial neoplasia(CIN).
Persistent infection with high-risk human papillomavirus (HPVs),especially types 16 and 18,may lead to cervical intraepithelial neoplasia(CIN).HPVs expresses the oncoproteins E6 and E7, both of which play key roles in maintaining viral infection and promoting carcinogenesis. Previous studies showed that using designated TALENs (T27 and T512) targeted HPV16 E6 and E7 produced disruption of HPV16 E6 and E7 DNA, decreased the expression of E6 and E7 proteins, and induced cell apoptosis. This study will evaluate the safety and efficacy of and T512 in treating HPV Persistency and HPV16-positive CIN. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
| Recruiting |
NCT04452526 -
I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination
|
N/A | |
| Active, not recruiting |
NCT03309033 -
Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study
|
||
| Not yet recruiting |
NCT03057912 -
A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ
|
Phase 1 | |
| Active, not recruiting |
NCT02800369 -
Study of Molecular-targeted Therapy Using Zinc Finger Nuclease in Cervical Precancerous Lesions
|
Phase 1 |